A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, "The ...

A phase 2/3 trial evaluates the efficacy and safety of neoadjuvant therapy with gemcitabine-oxaliplatin, lenvatinib, and ...

China: A neoadjuvant combination regimen comprising chemotherapy, targeted therapy, and immunotherapy has demonstrated significant clinical benefit in patients with resectable ...

ENHERTU Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer ...

"Optimal regimens and ideal patients remain undefined," experts say ...

Priority review and Project Orbis evaluation advance potential post-neoadjuvant use of trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease after neoadjuvant ...

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

The study explores the neoadjuvant approach: administering the immunotherapy drug Keytruda (pembrolizumab) before a surgeon ever picks up a scalpel. Researchers observed dramatic tumor shrinkage and, ...

The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.

In this article, we will look at the 12 Most Profitable Blue Chip Stocks to Invest In Now. On March 12, Stephen Parker, JPMorgan Private Bank co-head of global investment strategy, appeared on CNBC’s ...